SCHEMBL2908182

SCHEMBL2908182

COC(=O)c1cccc(N(Cc2cccnc2)c2ccc(F)c(OC3CCOC3)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 6/20 0.41
PDE4A P27815 4/20 0.41
PDE4B Q07343 4/20 0.41
PDE4C Q08493 4/20 0.41
ROCK2 O75116 1/20 0.38
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GRM2 Q14416 1/20 0.37
CHEK1 O14757 1/20 0.37
KDM4C Q9H3R0 1/20 0.36
GRM4 Q14833 1/20 0.36
USP2 O75604 1/20 0.36
EGFR P00533 1/20 0.35
ITK Q08881 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908178 1.00 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CROCK2
SCHEMBL2904821 0.91 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CCYP3A4
SCHEMBL2904824 0.91 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CCYP3A4
SCHEMBL2910456 0.86 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CTP53
SCHEMBL2910451 0.86 PDE4D (0.44) PDE4DPDE4APDE4BPDE4CTP53
SCHEMBL1157807 0.84 PDE4D (0.49) PDE4DPDE4APDE4BPDE4CSMN1; SMN2
SCHEMBL1157563 0.84 PDE4D (0.54) PDE4DPDE4APDE4BPDE4C
SCHEMBL1157644 0.82 PDE4D (0.49) PDE4DPDE4APDE4BPDE4CGRM2
SCHEMBL4194617 0.81 PDE4A (0.55) PDE4DPDE4APDE4BPDE4CTP53
SCHEMBL4195647 0.81 PDE4D (0.55) PDE4DPDE4APDE4BPDE4CGRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B PDE4D 6/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.